Abundant Produce adds more talent to its board
Published 24-MAY-2018 11:42 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Abundant Produce Limited (ASX:ABT) has today announced the appointment of new Board member, Seona Wallace.
Wallace is an established figure within the global skincare and pharmaceutical industry, and is a Board member of the Australian Self Medication Industry (ASMI). It is hoped her over 20 years’ experience and high profile will round out ABT’s already expert management team.
Wallace built her career working in senior commercial roles with multinational pharmaceutical companies including Sanofi and Boehringer Ingelheim. She has been Managing Director of leading healthcare group Health One since April 2015.
With her directorship added to the mix, ABT is in an ideal position to increase its market presence via Wallace’s innovative marketing approach that has seen her become an industry leader in product launches and go-to-market planning.
In addition, the company stated that Wallace would bring a broader range of perspectives to the table as well as increasing gender diversity among the team.
ABT CEO, Tony Crimmins said: “We will benefit greatly from Seona’s appointment to the Board, particularly with her exceptional, results driven track record and her comprehensive and complementary experience across the nutraceutical and skincare areas.
“As Managing Director, Seona has helped to position HealthOne as the fastest growing commercial healthcare partner in Australia. Through our sales, marketing and distribution agreement with HealthOne, we are establishing a foothold in the pharmacy channel with impressive potential for further growth.
“As a research focused company, we will benefit from Ms Wallace’s extensive experience in this area by gaining input at the early product development stage and translating it into a commercial proposition with the introduction of innovative products and sales strategies to ensure optimum results for ABT.”
Wallace also commented on her appointment: “I am thrilled to be joining Abundant at such an exciting time in product development. Launching to consumers in Australia is a huge opportunity to take Abundant to the next level and establish itself as a brand of choice in the pharmacy channel”.
ABT remains a speculative play and as such any investment decision should be made with caution and professional financial advice should be sought.
General Information Only
This material has been prepared by StocksDigital. StocksDigital is an authorised representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
